

Robert Pernecky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8129716/publications.pdf>

Version: 2024-02-01

166
papers

8,571
citations

50170

46
h-index

53109

85
g-index

181
all docs

181
docs citations

181
times ranked

12160
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Standardized ¹⁸ F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2008, 49, 390-398.	2.8	637
2	Mapping Scores Onto Stages: Mini-Mental State Examination and Clinical Dementia Rating. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 139-144.	0.6	564
3	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
4	A Pan-European Study of the <i>C9orf72</i> Repeat Associated with FTL: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	1.1	247
5	Amyloid β peptide ratio 42/40 but not $\text{A}\beta^{242}$ correlates with phospho τ in patients with low and high CSF $\text{A}\beta^{40}$ load. <i>Journal of Neurochemistry</i> , 2007, 101, 1053-1059.	2.1	237
6	Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. <i>Age and Ageing</i> , 2006, 35, 240-245.	0.7	227
7	Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 619-633.	2.1	201
8	Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 158-162.	1.3	198
9	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007, 34, 985-995.	2.1	162
10	Nutrition for the ageing brain: Towards evidence for an optimal diet. <i>Ageing Research Reviews</i> , 2017, 35, 222-240.	5.0	161
11	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010, 15, 138-145.	4.1	156
12	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.4	152
13	Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. <i>NeuroImage</i> , 2008, 40, 1503-1515.	2.1	151
14	Progression to Dementia in Clinical Subtypes of Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 27-34.	0.7	138
15	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	1.5	125
16	White matter hyperintensities predict amyloid increase in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 2766-2773.	1.5	115
17	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. <i>Neurobiology of Aging</i> , 2012, 33, 2533-2550.	1.5	108
18	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. <i>Journal of Nuclear Medicine</i> , 2013, 54, 894-902.	2.8	108

#	ARTICLE	IF	CITATIONS
19	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640.	5.8	108
20	Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2019, 15, 1468-1477.	0.4	106
21	Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ϵ 4 Genotype in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 879-884.	0.7	103
22	Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 69-77.	1.8	103
23	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	1.5	94
24	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	3.9	93
25	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 404-417.	0.7	90
26	Cerebral Metabolic Dysfunction in Patients with Dementia with Lewy Bodies and Visual Hallucinations. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 531-538.	0.7	88
27	Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. <i>Journal of Neural Transmission</i> , 2011, 118, 249-257.	1.4	88
28	A 6-month, open-label study of memantine in patients with frontotemporal dementia. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 754-759.	1.3	87
29	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	1.1	87
30	Meta-analyses identify differentially expressed microRNAs in Parkinson's disease. <i>Annals of Neurology</i> , 2019, 85, 835-851.	2.8	84
31	Impact of Alzheimers Disease on the Functional Connectivity of Spontaneous Brain Activity. <i>Current Alzheimer Research</i> , 2009, 6, 541-553.	0.7	83
32	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	3.7	83
33	Novel insights for the treatment of Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 373-379.	2.5	82
34	Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A ¹²³ I-β-CIT SPECT study. <i>Movement Disorders</i> , 2009, 24, 2097-2103.	2.2	73
35	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. <i>Neurology</i> , 2021, 96, .	1.5	72
36	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , 2019, 48, 912-925.	0.9	70

#	ARTICLE	IF	CITATIONS
37	Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. <i>BMC Medicine</i> , 2019, 17, 47.	2.3	69
38	TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. <i>Human Mutation</i> , 2005, 26, 29-35.	1.1	68
39	Amyloid Clearance as a Treatment Target Against Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 61-73.	1.2	67
40	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 815-826.	1.2	67
41	Patient Participation in Medical and Social Decisions in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2045-2052.	1.3	65
42	Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 939-954.	1.2	63
43	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
44	Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 684-689.	0.4	54
45	Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. <i>Neurobiology of Disease</i> , 2011, 43, 79-85.	2.1	52
46	Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	51
47	Rare variants in β -Amyloid precursor protein (APP) and Parkinson's disease. <i>European Journal of Human Genetics</i> , 2015, 23, 1328-1333.	1.4	50
48	Niemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders. <i>PLoS ONE</i> , 2013, 8, e82879.	1.1	50
49	Guilty by Suspicion? Criminal Behavior in Frontotemporal Lobar Degeneration. <i>Cognitive and Behavioral Neurology</i> , 2013, 26, 73-77.	0.5	49
50	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017, 12, e0179521.	1.1	48
51	Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 553-560.	1.8	47
52	Plasma Proteomics for the Identification of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 337-342.	0.6	47
53	Metabolic connectivity for differential diagnosis of dementing disorders. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 252-262.	2.4	47
54	Brain size and the compensation of Alzheimer's disease symptoms: A longitudinal cohort study. <i>Alzheimer's and Dementia</i> , 2013, 9, 580-586.	0.4	46

#	ARTICLE	IF	CITATIONS
55	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2019, 74, 182-190.	1.5	45
56	Cerebral Metabolic Correlates of the Clinical Dementia Rating Scale in Mild Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007, 20, 84-88.	1.2	44
57	miRNAs Identify Shared Pathways in Alzheimer's and Parkinson's Diseases. <i>Trends in Molecular Medicine</i> , 2019, 25, 662-672.	3.5	44
58	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855.	4.1	43
59	Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1082-1087.	3.3	42
60	Education Attenuates the Effect of Medial Temporal Lobe Atrophy on Cognitive Function in Alzheimer's Disease: The MIRAGE Study. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 855-862.	1.2	42
61	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
62	Non-fluent progressive aphasia: Cerebral metabolic patterns and brain reserve. <i>Brain Research</i> , 2007, 1133, 178-185.	1.1	40
63	Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimer's Disease Cerebrospinal Fluid Markers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 164-170.	0.7	39
64	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
65	Male gender is associated with greater cerebral hypometabolism in frontotemporal dementia: evidence for sex-related cognitive reserve. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 1135-1140.	1.3	38
66	Urinary incontinence and its functional anatomy in frontotemporal lobar degenerations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 605-610.	3.3	37
67	In Vivo Assessment of Neuroinflammation in Repeat Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894.	2.2	37
68	Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0122731.	1.1	37
69	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	1.3	37
70	No association of TDP-43 with sporadic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2009, 30, 157-159.	1.5	36
71	Age-related cerebral perfusion changes in the parietal and temporal lobes measured by pulsed arterial spin labeling. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 1295-1302.	1.9	35
72	Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S425-S429.e1.	0.4	35

#	ARTICLE	IF	CITATIONS
73	Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends in Molecular Medicine, 2014, 20, 8-15.	3.5	35
74	Activities of Daily Living, Cerebral Glucose Metabolism, and Cognitive Reserve in Lewy Body and Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 475-481.	0.7	34
75	Relationship between occupation attributes and brain metabolism in frontotemporal dementia. Neuropsychologia, 2011, 49, 3699-3703.	0.7	34
76	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
77	Determinants of self- and carer-rated quality of life and caregiver burden in Alzheimer disease. International Journal of Geriatric Psychiatry, 2019, 34, 1378-1385.	1.3	32
78	Metabolic Correlates of Brain Reserve in Dementia with Lewy Bodies: An FDG PET Study. Dementia and Geriatric Cognitive Disorders, 2007, 23, 416-422.	0.7	31
79	Which medical and social decision topics are important after early diagnosis of Alzheimer's Disease from the perspectives of people with Alzheimer's Disease, spouses and professionals?. BMC Research Notes, 2016, 9, 149.	0.6	31
80	Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. BMC Medicine, 2016, 14, 162.	2.3	30
81	Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2020, 73, 1615-1626.	1.2	29
82	Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A β -PET and cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1289-1295.	0.9	29
83	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	3.3	29
84	Association of the Tau Haplotype H2 With Age at Onset and Functional Alterations of Glucose Utilization in Frontotemporal Dementia. American Journal of Psychiatry, 2007, 164, 1577-1584.	4.0	28
85	Fluoro-Deoxy-Glucose Positron Emission Tomography Correlates of Impaired Activities of Daily Living in Dementia With Lewy Bodies: Implications for Cognitive Reserve. American Journal of Geriatric Psychiatry, 2009, 17, 188-195.	0.6	28
86	Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. , 2012, 8, 304-311.		28
87	The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 325-333.	1.8	27
88	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. Neuron, 2022, 110, 1009-1022.e4.	3.8	27
89	Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. Neurobiology of Aging, 2009, 30, 1420-1429.	1.5	25
90	Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET. PLoS ONE, 2013, 8, e55415.	1.1	25

#	ARTICLE	IF	CITATIONS
91	Neurobiology of cognitive disorders. <i>Current Opinion in Psychiatry</i> , 2009, 22, 546-551.	3.1	24
92	SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 529-534.	1.8	24
93	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. <i>Neurology</i> , 2020, 94, e861-e873.	1.5	24
94	Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1916-1921.	2.8	22
95	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	3.3	22
96	Interrelations between CSF Soluble A β 1-42, Amyloid- β 1-42, SORL1, and Tau Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 543-552.	1.2	21
97	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. <i>Frontiers in Neurology</i> , 2018, 9, 483.	1.1	21
98	Asymmetric Loss of Parietal Activity Causes Spatial Bias in Prodromal and Mild Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 798-804.	0.7	20
99	Cortisol, Amyloid- β , and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 553-562.	1.2	20
100	Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 51.	3.0	19
101	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
102	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. <i>Molecular Psychiatry</i> , 2022, 27, 2019-2029.	4.1	19
103	DO ALL PATIENTS WITH MILD COGNITIVE IMPAIRMENT PROGRESS TO DEMENTIA?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1008-1010.	1.3	18
104	β -Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. , 2013, 9, 386-391.		18
105	Cerebrospinal Fluid BACE1 Activity and sA β 1-42 as Biomarker Candidates of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 152-161.	0.7	18
106	Brain Metabolic Correlates of Cerebrospinal Fluid Beta-Amyloid 42 and Tau in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 474-480.	0.7	17
107	Amyloid Cascade and Tau Pathology Cerebrospinal Fluid Markers in Mild Cognitive Impairment with regards to Alzheimer's Disease Cerebral Metabolic Signature. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 401-408.	1.2	17
108	Small Vessel Disease, but Neither Amyloid Load nor Metabolic Deficit, Is Dependent on Age at Onset in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 704-710.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Dementia prevention and reserve against neurodegenerative disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 53-60.	1.8	17
110	Dementia treatment versus prevention. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 43-51.	1.8	17
111	Interpreting PET scans by structured patient data: a data mining case study in dementia research. <i>Knowledge and Information Systems</i> , 2010, 24, 149-170.	2.1	15
112	LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's disease in humans in-vivo. <i>NeuroImage: Clinical</i> , 2014, 4, 411-416.	1.4	15
113	Mapping CSF biomarker profiles onto NIA's AA guidelines for Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 587-597.	1.8	14
114	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101949.	1.4	14
115	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 383-394.	1.2	14
116	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE ϵ ₄ /TOMM40 long poly ϵ repeat allele variants. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 814-824.	1.8	14
117	Prioritizing problems in and solutions to homecare safety of people with dementia: supporting carers, streamlining care. <i>BMC Geriatrics</i> , 2017, 17, 26.	1.1	13
118	The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. <i>Respiratory Research</i> , 2019, 20, 257.	1.4	13
119	Dual-Phase β -Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284.	1.7	13
120	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. <i>NeuroImage: Clinical</i> , 2021, 29, 102535.	1.4	13
121	Evaluation of liraglutide in the treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	13
122	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. <i>Cerebral Cortex</i> , 2021, 31, 4901-4915.	1.6	12
123	Metabolic alterations associated with impaired clock drawing in Lewy body dementia. <i>Psychiatry Research - Neuroimaging</i> , 2010, 181, 85-89.	0.9	11
124	Plasma Proteomics Biomarkers in Alzheimer's Disease: Latest Advances and Challenges. <i>Methods in Molecular Biology</i> , 2016, 1303, 521-529.	0.4	11
125	Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 519-524.	1.8	11
126	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	1.1	11

#	ARTICLE	IF	CITATIONS
127	Risk of Late-Onset Depression and Cognitive Decline: Results From Inflammatory Proteome Analyses in a Prospective Population-Based Cohort Study. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 689-700.	0.6	11
128	Accelerated clinical decline in well-educated patients with frontotemporal lobar degenerations. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 362-367.	1.8	10
129	Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	0.8	10
130	Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β^2 at PET Imaging. <i>Radiology</i> , 2020, 296, 134-142.	3.6	10
131	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
132	Biomarkers and Functional Decline in Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 69-78.	1.2	9
133	Interpreting PET Scans by Structured Patient Data: A Data Mining Case Study in Dementia Research. , 2008, , .		8
134	Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2019, 19, 43-50.	0.8	7
135	General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 98-104.	1.1	7
136	Efficient redundancy reduced subgroup discovery via quadratic programming. <i>Journal of Intelligent Information Systems</i> , 2015, 44, 271-288.	2.8	5
137	Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 193-201.	1.4	5
138	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	1.6	4
139	Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cohort (PRO) SubStudy. <i>BMJ Open</i> , 2021, 11, e043114.	0.8	4
140	A Case Study of Stacked Multi-view Learning in Dementia Research. <i>Lecture Notes in Computer Science</i> , 2011, , 60-69.	1.0	3
141	Associations between APOE-, COMT Val108/158Met- and BDNF Val66Met polymorphisms and variations in depressive and anxiety symptoms, sense of coherence and vital exhaustion in the real-life setting of mandatory basic military training. <i>Journal of Neural Transmission</i> , 2021, 128, 105-114.	1.4	3
142	Population-Based Approaches to Alzheimer's Disease Prevention. <i>Methods in Molecular Biology</i> , 2018, 1750, 15-29.	0.4	3
143	Anti-Dementia Medications and Anti-Alzheimer's Disease Drugs: Side Effects, Contraindications, and Interactions. , 2022, , 1-10.		3
144	Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 399-404.	3.3	2

#	ARTICLE	IF	CITATIONS
145	Dealing with uncertainty: biomarkers for the early detection of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2012, 24, 1533-1535.	0.6	2
146	How would a decision to leave the European Union affect medical research and health in the United Kingdom?. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 216-218.	1.1	2
147	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	1.7	2
148	COGNITIVE RESERVE, HOMOCYSTEINE, AND COGNITION IN THE BAVARIAN SCHOOL SISTERS STUDY. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1754-1756.	1.3	1
149	Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges. <i>Neuromethods</i> , 2018, , 179-187.	0.2	1
150	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
151	Gender differences in the moderating capacity of reserve and resilience factors on the association of Alzheimer's disease brain pathology and cognitive function. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
152	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
153	The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2013, 10, 82-85.	0.7	0
154	Plasma Levels of Soluble A β 1-42 as a Biomarker for Alzheimer's Disease with Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 83-90.	1.2	0
155	Microglial activation and brain networks in Alzheimer's disease: The ActiGliA cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043265.	0.4	0
156	Persönlichkeitsstörungen im Alter. , 2021, , 319-325.		0
157	The multidimensional beneficial effect of physical exercise on symptoms of neurocognitive disorder. <i>International Psychogeriatrics</i> , 2021, , 1-4.	0.6	0
158	Persönlichkeitsstörungen im Alter. , 2017, , 263-269.		0
159	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
160	A residual marker of cognitive reserve modifies the cross-sectional and longitudinal association between memory and glucose hypometabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
161	Longitudinal changes of phosphorylated tau 181 and neurofilament light chain in plasma and their associations with tau and amyloid PET. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
162	Comparison of latent cognitive reserve markers and a latent marker score in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	Characterization of the NIAâ€ˆAA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
164	Feasibility of short imaging protocols for [¹⁸ F]Piâ€ˆ2620 tauâ€ˆPET in progressive supranuclear palsy. Alzheimer's and Dementia, 2021, 17, .	0.4	0
165	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimerâ€™s disease: The first step towards comprehensive artificial intelligence. Alzheimer's and Dementia, 2021, 17, .	0.4	0
166	Prediction of amyloidâ€ˆpositivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€ˆneededâ€ˆtoâ€ˆscreen. Alzheimer's and Dementia, 2021, 17, .	0.4	0